Posted On: 10/30/2012 9:45:24 PM
Post# of 72436
![Avatar](https://investorshangout.com/images/ProfileImages/1643501336_3053_jed-clampett.jpg)
Re: biomanbaba #461
Change the landscape
“We are extremely pleased to hear that the first patients will begin therapy with Kevetrin™ in a matter of days,” said Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. “Not only is this is a substantial milestone for Cellceutix and its shareholders, but we feel it is important to the field of oncology. As a novel compound that directly impacts p53, the “Guardian Angel of the Human Genome,” we look forward to a steady patient enrollment and future outcomes that potentially could change the landscape of cancer therapeutics.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)